PriceTargets.com logo

Kiora Pharmaceuticals - KPRX Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 201.20%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$3.32 As of 12/18/2024 04:07 PM ET
▼ -0.17 (-4.87%)

This chart shows the closing price for KPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kiora Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KPRX

Analyst Price Target is $10.00
▲ +201.20% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Kiora Pharmaceuticals in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 201.20% upside from the last price of $3.32.

This chart shows the closing price for KPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 2 contributing investment analysts is to buy (strong buy) stock in Kiora Pharmaceuticals. This rating has held steady since May 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
7/23/2024HC WainwrightBoost TargetBuy ➝ Buy$2.00 ➝ $10.00
6/13/2024Maxim GroupUpgradeStrong-Buy
5/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy
8/24/2023HC WainwrightReiterated RatingBuy ➝ Buy
5/12/2023HC WainwrightBoost Target$54.00 ➝ $63.00
2/9/2023Maxim GroupUpgradeHold ➝ Buy$108.00
2/8/2023LADENBURG THALM/SH SHReiterated RatingBuy$1,071.00
2/8/2023HC WainwrightReiterated RatingBuy$90.00
8/25/2022LADENBURG THALM/SH SHInitiated CoverageBuy
8/15/2022Maxim GroupDowngradeBuy ➝ Hold
7/11/2022HC WainwrightLower TargetBuy$1,080.00 ➝ $900.00
5/26/2022Maxim GroupLower Target$360.00
4/19/2022HC WainwrightLower TargetBuy$1,800.00 ➝ $1,080.00
1/19/2022Maxim GroupInitiated CoverageBuy$900.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Kiora Pharmaceuticals logo
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Read More

Today's Range

Now: $3.32
Low: $3.32
High: $3.84

50 Day Range

MA: $3.48
Low: $3.10
High: $4.04

52 Week Range

Now: $3.32
Low: $3.00
High: $8.98

Volume

92,800 shs

Average Volume

69,981 shs

Market Capitalization

$9.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kiora Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Kiora Pharmaceuticals in the last year: HC Wainwright, and Maxim Group.
View the latest analyst ratings for KPRX.

What is the current price target for Kiora Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Kiora Pharmaceuticals in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 201.2%. HC Wainwright has the highest price target set, predicting KPRX will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Kiora Pharmaceuticals in the next year.
View the latest price targets for KPRX.

What is the current consensus analyst rating for Kiora Pharmaceuticals?

Kiora Pharmaceuticals currently has 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for KPRX.

What other companies compete with Kiora Pharmaceuticals?

Other companies that are similar to Kiora Pharmaceuticals include Estrella Immunopharma, BioVie, Aileron Therapeutics, Virios Therapeutics and Q32 Bio. Learn More about companies similar to Kiora Pharmaceuticals.

How do I contact Kiora Pharmaceuticals' investor relations team?

Kiora Pharmaceuticals' physical mailing address is 271 Waverley Oaks Rd Ste 108, Waltham, Massachusetts 02452-8475. The company's listed phone number is (781) 788-9043 and its investor relations email address is [email protected]. The official website for Kiora Pharmaceuticals is eyegatepharma.com. Learn More about contacing Kiora Pharmaceuticals investor relations.